Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2021
>
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
Read also
Chronic Babesiosis Treatment: DSMB Backs Tafenoquine Clinical Trials
The DSMB recommends 60 Degrees Pharmaceuticals continue its Phase 2 B-FREE clinical trial of tafenoquine to treat persistent fatigue in chronic babesiosis.
Celea Therapeutics Secures $180M for Phase 3 IPF Clinical Trials Test
Celea Therapeutics secured $180 million for the Phase 3 SURPASS-IPF trial of deupirfenidone, a promising new treatment for idiopathic pulmonary fibrosis.
WHO Begins Clinical Trials For New Ebola Virus Treatments in DR Congo.
The WHO has launched clinical trials in DR Congo to evaluate MBP134 and remdesivir as potential treatments for the deadly Bundibugyo Ebola virus strain.
New Remote Blood Cancer Clinical Trials Launched for Guernsey Patients
Guernsey blood cancer patients can now join UK clinical trials remotely. A new initiative transports excess tissue and blood samples to advance cancer research.
